Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier

Journal of Pharmaceutical Sciences

Volumn 95, Issue 1, 2006, Pages 70-79

  Ionescu, Roxana M ^a   Przysiecki, Craig T ^a   Liang, Xiaoping ^a   Garsky, Victor M ^a   Fan, Jiang ^a   Wang, Bei ^a   Troutman, Robert ^a   Rippeon, Yvette ^a   Flanagan, Elizabeth ^a   Shiver, John ^a   Shi, Li ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Analytical ultracentrifugation; Light scattering (dynamic); Peptide delivery; Protein carrier; Protein structure; Stability

Indexed keywords

ALUMINUM; CYSTEINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; PROTEIN M2; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VACCINE; INFLUENZA VACCINE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; IMMUNOGENICITY; INFLUENZA A; MOUSE; NONHUMAN; PARTICLE SIZE; VACCINE PRODUCTION; VIRUS PARTICLE; WART VIRUS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; INFLUENZA VIRUS A; PAPILLOMA VIRUS; PATHOGENICITY; SURVIVAL; VACCINATION; VIRION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DRUG CARRIERS; FEMALE; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; PAPILLOMAVIRIDAE; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, CONJUGATE; VIRAL MATRIX PROTEINS; VIRION;

EID: 33645217860     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20493     Document Type: Article

References (30)

1. Arnon R, Ben-Yedidia T. 2003. Old and new vaccine approaches. Int Immunopharmacol 3:1195-1204.
2. Beekman NJ, Schaaper WM, Turkstra JA, Meloen RH. 1999. Highly immunogenic and fully synthetic peptide-carrier constructs targeting GnRH. Vaccine 17:2043-2050.
3. Olive C, Batzloff M, Horvath A, Clair T, Yarwood P, Toth I, Good MF. 2003. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 71:2373-2383.
4. Yip YL, Smith G, Ward RL. 2001. Comparison of phage pIII, pVIII and GST as carrier proteins for peptide immunization in Balb/c mice. Immunol Lett 79:197-202.
5. Rauly I, Goetsch L, Haeuw JF, Tardieux C, Baussant T, Bonnefoy JY, Corvaia N. 1999. Carrier properties of a protein derived from outer Membrane protein A of Klebsiella pneumoniae. Infect Immun 67:5547-5551.
6. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu RM, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies M, Liao J, Emini EA, Shiver J. 2004. Preclinical study of Influenza Virus A M2 peptide conjugate vaccines in mice, ferrets and rhesus monkeys. Vaccine 22:2993-3003.
7. Domingo GJ, Caivano A, Sartorius R, Barba P, Backstrom M, Piatier-Tonneau D, Guardiola J, De Berardinis P, Perham N. 2003. Induction of specific T-helper and cytolytic responses to epitopes displayed on a virus-like protein scaffold derived from the pyruvate dehydrogenase multienzyme complex. Vaccine 21:1502-1509.
8. Pumpens P, Razanskas R, Pushko P, Renhof R, Gusars I, Skrastina D, Ose V, Borisova G, Sominskaya I, Petrovskis I, Jansons J, Sasnauskas K. 2002. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology 45:24-32.
9. Niikura M, Takamura S, Kim G, Kawai S, Saijo M, Morikawa S, Kurane I, Li TC, Takeda N, Yasutomi Y. 2002. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 293:273-280.
10. Gedvilaite A, Frommel C, Sasnauskas K, Micheel B, Ozel M, Behrsing O, Staniulis J, Jandrig B, Scherneck S, Ulrich R. 2000. Formation of Immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 273:21-35.
11. Chackerian B, Lowy DR, Schiller JT. 2001. Conjugation of self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108:415-423.
12. Karpenko LI, Lebedev LR, Ignatyev GM, Agafonov AP, Poryvaeva VA, Pronyaeva TR, Ryabchikova EI, pokrovsky AG, Ilyichev AA. 2003. Construction of artificial virus-like particles exposing HIV epitopes and the study of their immunogenic properties. Vaccine 21:386-392.
13. hackerian B, Lowy DR, Schiller JT. 1999. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 96:2373-2378.
14. Chen XS, Garcea RL, Goldber I, Casini G, Harrison SC. 2000. Structure of small viruslike-particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5:557-567.
15. Modis Y, Trus BL, Harrison SC. 2002. Atomic model of the papilloma virus capsid. EMBO J 21:4754-4762.
16. Greenstone HL, Nieland JD, De Vissier KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT. 1998. Chimeric papillomavirus virus-like particle elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc Natl Acad Sci USA 95:1800-1805.
17. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-1163.
18. Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L, Chen L, Cook JC, McClemens WL, Jansen KU. 2003. Effect of vaccine delivery system on the induction of HPV16 L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 21:1539-1547.
19. Shuler KR, Dunham RG, Kanda P. 1992. A simplified method for determination of peptide-protein molar ratios using amino acid analysis. J Immunol Meth 156:137-149.
20. White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim S, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, Suzich JA. 1999. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1 J Virol 73:4882-4889.
21. Tian C, Gao PF, Pinto LH, Lamb RA, Cross TA. 2003. Initial structural and dynamic characterization of the M2 protein transmembrane and amphipathic helices in lipid bilayers. Prot Sci 12:2597-2605.
22. Shah S, Raghupathy R, Singh O, Talwar GP, Sodhi A. 1999. Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine. Vaccine 17:3116-3123.
23. Lise LD, Mazier D, Jolivet AM, Chedid L, Schlesinger D. 1987. Enhanced epitopic response to a synthetic human malarial peptide by pre-immunization with tetanus toxid carrier. Infect Immun 55:2658-2661.
24. Ben-Yedidia T, Arnon R. 1998. Effect of pre-existing immunity on the efficacy of synthetic influenza vaccine. Immunol Lett 64:9-15.
25. Wang Z, Christensen N, Schiller JT, Dillner J. 1997. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78:2209-2215.
26. Koradi R, Billeter M, Wutrich K. 1996. MOLMOL: A program for display and analysis of macromolecular structures. J Mol Graphics 14:51-55.
27. Van Regenmortel MHV. 2001. Pitfalls of reductionism in the design of peptide-based vaccines. Vaccine 19:2369-2374.
28. Van Endert PM. 2001. Designing peptide vaccines for cellular cross-presentation. Biologicals 29:285-288.
29. Meloen RH, Langeveld JPM, Schaaper WMM, Slootstra JW. 2001. Synthetic peptide vaccines: Unexpected fulfillment of discarded hope? Biologicals 29:233-236.
30. Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen YH. 2004. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 23:366-371.